CN102341102A - 嘧啶基氨基苯甲酰胺衍生物用于治疗由包含亮氨酸拉链和不育α基序的激酶(ZAK)介导的疾病的用途 - Google Patents

嘧啶基氨基苯甲酰胺衍生物用于治疗由包含亮氨酸拉链和不育α基序的激酶(ZAK)介导的疾病的用途 Download PDF

Info

Publication number
CN102341102A
CN102341102A CN2010800105713A CN201080010571A CN102341102A CN 102341102 A CN102341102 A CN 102341102A CN 2010800105713 A CN2010800105713 A CN 2010800105713A CN 201080010571 A CN201080010571 A CN 201080010571A CN 102341102 A CN102341102 A CN 102341102A
Authority
CN
China
Prior art keywords
lower alkyl
mono
phenyl
amino
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800105713A
Other languages
English (en)
Chinese (zh)
Inventor
D·法布罗
P·W·曼雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN102341102A publication Critical patent/CN102341102A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2010800105713A 2009-03-06 2010-03-05 嘧啶基氨基苯甲酰胺衍生物用于治疗由包含亮氨酸拉链和不育α基序的激酶(ZAK)介导的疾病的用途 Pending CN102341102A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09154507 2009-03-06
EP09154507.9 2009-03-06
EP09166437 2009-07-27
EP09166437.5 2009-07-27
PCT/EP2010/052797 WO2010100248A1 (en) 2009-03-06 2010-03-05 Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper- and sterile alpha motif-containing kinase (zak)

Publications (1)

Publication Number Publication Date
CN102341102A true CN102341102A (zh) 2012-02-01

Family

ID=42115422

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800105713A Pending CN102341102A (zh) 2009-03-06 2010-03-05 嘧啶基氨基苯甲酰胺衍生物用于治疗由包含亮氨酸拉链和不育α基序的激酶(ZAK)介导的疾病的用途

Country Status (11)

Country Link
US (1) US20120015968A1 (enExample)
EP (1) EP2403492A1 (enExample)
JP (1) JP2012519668A (enExample)
KR (1) KR20110132439A (enExample)
CN (1) CN102341102A (enExample)
AU (1) AU2010220262B2 (enExample)
BR (1) BRPI1013366A2 (enExample)
CA (1) CA2753637A1 (enExample)
MX (1) MX2011009310A (enExample)
RU (1) RU2011140404A (enExample)
WO (1) WO2010100248A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108117553A (zh) * 2016-11-30 2018-06-05 暨南大学 炔苯基苯磺酰胺类选择性zak抑制剂及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6697311B2 (ja) * 2016-04-01 2020-05-20 ショーワグローブ株式会社 手袋

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101185627A (zh) * 2007-12-14 2008-05-28 山东蓝金生物工程有限公司 一种治疗实体肿瘤的尼罗替尼缓释植入剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429599B2 (en) * 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
JP4552650B2 (ja) 2002-06-28 2010-09-29 日本新薬株式会社 アミド誘導体及び医薬
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
KR20060130619A (ko) * 2004-01-22 2006-12-19 노파르티스 아게 유기 화합물의 조합물
WO2005118833A2 (en) * 2004-06-01 2005-12-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with sterile-alpha motif and leucine zipper containing kinase (zak)
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
EP1915154A2 (en) * 2005-08-11 2008-04-30 Novartis AG Combination of organic compounds
WO2007051862A1 (en) * 2005-11-07 2007-05-10 Novartis Ag Combination of organic compounds
EA200970447A1 (ru) * 2006-11-03 2009-10-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
EP2089003A1 (en) * 2006-11-09 2009-08-19 Abbott GmbH & Co. KG Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101185627A (zh) * 2007-12-14 2008-05-28 山东蓝金生物工程有限公司 一种治疗实体肿瘤的尼罗替尼缓释植入剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHU S 等: "Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors", 《GYNECOLOGIC ONCOLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108117553A (zh) * 2016-11-30 2018-06-05 暨南大学 炔苯基苯磺酰胺类选择性zak抑制剂及其应用
CN108117553B (zh) * 2016-11-30 2019-08-16 暨南大学 炔苯基苯磺酰胺类选择性zak抑制剂及其应用

Also Published As

Publication number Publication date
JP2012519668A (ja) 2012-08-30
AU2010220262B2 (en) 2014-01-09
KR20110132439A (ko) 2011-12-07
BRPI1013366A2 (pt) 2016-03-29
US20120015968A1 (en) 2012-01-19
CA2753637A1 (en) 2010-09-10
EP2403492A1 (en) 2012-01-11
RU2011140404A (ru) 2013-04-20
AU2010220262A1 (en) 2011-09-08
MX2011009310A (es) 2011-10-13
WO2010100248A1 (en) 2010-09-10

Similar Documents

Publication Publication Date Title
AU2016216636B2 (en) Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
US8604045B2 (en) Pyrimidylaminobenzamide derivatives for treatment of neurofibromatosis
US20100022569A1 (en) Inhibitors of tyrosine kinases
CN102341102A (zh) 嘧啶基氨基苯甲酰胺衍生物用于治疗由包含亮氨酸拉链和不育α基序的激酶(ZAK)介导的疾病的用途
KR20080004563A (ko) 전신 비만세포증의 치료를 위한 피리미딜아미노벤즈아미드유도체의 용도
RU2415672C2 (ru) Производные пиримидиламинобензамида для лечения синдрома гиперэозинофилии
EP2186514B1 (en) Treatment of Malignant Peripheral Nerve Sheath Tumors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120201